S. Louise Phanstiel - Aug 5, 2021 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role
Director
Signature
By: Nathan A. Smith For: S. Louise Phanstiel
Stock symbol
MYGN
Transactions as of
Aug 5, 2021
Transactions value $
-$277,341
Form type
4
Date filed
8/6/2021, 05:43 PM
Previous filing
Jul 2, 2021
Next filing
Jan 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Options Exercise $762K +30K +37.72% $25.39 110K Aug 5, 2021 Direct
transaction MYGN Common Stock Sale -$1.68M -47.9K -43.72% $35.04 61.6K Aug 5, 2021 Direct F1
transaction MYGN Common Stock Options Exercise $639K +30K +48.66% $21.29 91.6K Aug 5, 2021 Direct
holding MYGN Common Stock 21K Aug 5, 2021 The Phanstiel Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -30K -100% $0.00* 0 Aug 5, 2021 Common Stock 30K $21.29 Direct F2
transaction MYGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -30K -100% $0.00* 0 Aug 5, 2021 Common Stock 30K $25.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.49 to $35.50, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The shares subject to this option are fully vested and exercisable.